Artiva Biotherapeutics Inc. Common Stock (ARTV)
Stock · NASDAQ · Health Care
$5.86as of 10/16/2026
Price chart
Active signals
ARTV Signal Track Record
How signals performed across all stocks →What ARTV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 11 | +11.6% | 55% | September 10, 2026 |
| Bollinger Band Breakout | 9 | +4.2% | 56% | July 28, 2026 |
| Bollinger Band Breakdown | 6 | +20.9% | 83% | September 10, 2026 |
| Any 20-session window (baseline) | +8.5% | 60% |
Computed by MarketWall from daily closing prices since May 6, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ARTV
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis,…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 115
- Website
- www.artivabio.com/
Fundamentals
- 1-day range
- $5.82$6.1
- Market cap
- $566.10M
- P/E (trailing)
- —
- P/E (forward)
- -2.24
- EPS (trailing)
- $-3.43
- Dividend yield
- —
- Beta
- 5.95
- Avg. volume
- 401.7K
How Artiva Biotherapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 24, 2025 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Artiva Biotherapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ARTVArtiva Biotherapeutics Inc. Common Stock$5.85▼ 3.47%Market cap $566.10MP/E —$2.75$14.53
- TECXTectonic Therapeutic Inc. Common Stock$20.65▼ 3.05%Market cap $570.23MP/E —$14.6$39.53
- FDMT4D Molecular Therapeutics Inc. Common Stock$12.14▼ 5.67%Market cap $551.51MP/E —$6.96$16.93
- RGNXREGENXBIO Inc. Common Stock$6.93▼ 3.28%Market cap $583.15MP/E —$5.46$16.19
- ZURAZura Bio Limited Class A Ordinary Shares$3.88▼ 9.35%Market cap $542.44MP/E —$3.15$7.44
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ARTV Artiva Biotherapeutics Inc. Common Stock | $566.10M | — | $5.85 | ▼ 3.47% | $2.75$14.53 |
| TECX Tectonic Therapeutic Inc. Common Stock | $570.23M | — | $20.65 | ▼ 3.05% | $14.6$39.53 |
| FDMT 4D Molecular Therapeutics Inc. Common Stock | $551.51M | — | $12.14 | ▼ 5.67% | $6.96$16.93 |
| RGNX REGENXBIO Inc. Common Stock | $583.15M | — | $6.93 | ▼ 3.28% | $5.46$16.19 |
| ZURA Zura Bio Limited Class A Ordinary Shares | $542.44M | — | $3.88 | ▼ 9.35% | $3.15$7.44 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026Yahoo · 10/2/2026
- Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price TargetBenzinga · 10/2/2026
- Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)Yahoo · 10/1/2026
- Artiva Biotherapeutics Presents Updated Clinical, Safety And Translational Data For AlloNK In Combination With Rituximab At 17th ISSjD 2026 In ParisBenzinga · 10/1/2026
- Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s DiseaseYahoo · 9/23/2026
- Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation ForumYahoo · 9/17/2026
Insider Activity
Insider Actions →- Aslan Fred · October 6, 2026 · Sale23.5K @ $7.2
- Banerjee Subhashis · October 5, 2026 · Sale1.1K @ $6.84
- Aslan Fred · October 5, 2026 · Sale61.7K @ $6.84
- Horan Christopher · October 5, 2026 · Sale10.3K @ $6.84
- Bush Jennifer · October 5, 2026 · Sale8.4K @ $6.84
- Aslan Fred · September 15, 2026 · Grant315.0K
- Aslan Fred · September 15, 2026 · Grant110.0K
- Aslan Fred · September 10, 2026 · Grant155.0K
- Aslan Fred · September 10, 2026 · Grant45.0K
- Laura Stoppel · September 10, 2026 · Grant16.3K
- Sorg Elaine K. · September 10, 2026 · Grant16.3K
- Baker Daniel G. · September 10, 2026 · Grant16.3K
- Alison Moore · September 10, 2026 · Grant16.3K
- DANIELS BRIAN · September 10, 2026 · Grant16.3K
- RA CAPITAL MANAGEMENT, L.P. · September 10, 2026 · Grant16.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 16.80M
- Total value held
- $108.21M
- Institutional holders
- 38
- Unknown9.85M
- Unknown2.35M
- Unknown1.61M
- Unknown531.3K
- Unknown520.3K
- Unknown299.3K
- Unknown213.4K
- Unknown207.7K
- Unknown194.1K
- Unknown146.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium
Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium. Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.